Immature platelet biomarkers in maintenance hemodialysis patients: baseline assessment and changes during a single hemodialysis session
In clinically stable maintenance hemodialysis patients, a single hemodialysis session induces acute increases in immature platelet indices and IL-6 alongside a reduction in mean platelet component, suggesting transient alterations in platelet turnover and activation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of people around the world, life depends on a machine that acts as an artificial kidney. This treatment, known as hemodialysis, filters waste and excess fluid from the blood when the body's own kidneys can no longer do the job. While this procedure keeps patients alive, it is not a passive experience for the blood itself. Every time blood flows through the dialysis machine, it encounters foreign surfaces and mechanical forces that can irritate the body's natural clotting system. This creates a difficult situation for patients: they are often at risk of bleeding because their blood does not clot well, yet they are also at risk of dangerous clots forming because the treatment itself can over-activate the clotting cells. To understand this paradox, scientists have begun looking closely at the youngest members of the blood's clotting army. These are called immature platelets. Unlike their mature counterparts, which are fully formed and ready for duty, immature platelets are newly released from the bone marrow. They are larger, contain more genetic material, and are more eager to react to injury. Because they are so active, they play a special role in how the body responds to stress, including the stress of a dialysis session.
A team of researchers at the IRCCS Policlinico San Matteo in Italy set out to see what happens to these young blood cells during a single dialysis treatment. They followed sixty-four patients who were receiving regular maintenance dialysis. Before the treatment began, the researchers took a blood sample to measure the number of platelets, the proportion of immature ones, and a measure of how dense the platelets were inside. They also checked levels of a protein called interleukin-6, which is a marker of inflammation in the body. After the session was complete, they took another sample to see how the numbers had changed. The goal was not to test a new drug or a new machine, but simply to observe the immediate biological reaction of the blood to the procedure.
The results revealed a dynamic shift that was hidden when looking only at the total number of platelets. The overall count of platelets in the blood remained exactly the same before and after the session, suggesting that the blood volume was stable. However, the composition of that blood had changed significantly. The researchers found that the fraction of immature platelets increased noticeably, rising from an average of 2.1 percent before treatment to 2.6 percent afterward. At the same time, the average density of the platelets dropped. In the world of blood cells, a drop in density is a sign that the cells have been activated and have released their internal contents, much like a sponge that has been squeezed and is now less dense. This combination of more young cells and less dense cells suggests that the dialysis session triggered a rapid response: the body likely consumed some platelets during the procedure and immediately released fresh, young ones from the bone marrow to replace them, while the existing cells became more active.
The study also looked at what factors might influence these changes. The researchers discovered that the size of the increase in immature platelets was linked to two specific things: the age of the patient and the amount of heparin, an anticoagulant drug, used during the session. Patients who received higher doses of heparin saw a larger rise in immature platelets, while older patients saw a smaller rise. Interestingly, the length of time the patient spent on the machine did not seem to matter. The researchers also noted that the rise in immature platelets was not simply caused by the blood becoming more concentrated as fluid was removed from the body. If it were just a matter of concentration, the changes would have been uniform across all measurements, but the specific pattern of young cells rising and density falling pointed to a biological reaction rather than a physical one.
Despite these clear changes in the blood markers, the study did not find evidence that the patients' blood became more resistant to their usual medications. About two-thirds of the patients were taking drugs designed to prevent clots, such as aspirin or clopidogrel. The researchers compared the blood changes in those taking these drugs with those who were not and found no difference. This suggests that while the dialysis session stirs up the blood and brings out young, active cells, it does not immediately cancel out the effect of the anti-clotting medication the patients are taking. However, the authors are careful to state that this study only looked at the blood at the very beginning and very end of a single session. They did not measure how well the platelets actually functioned or whether these changes led to more heart attacks or strokes in the long run.
The findings offer a new window into the complex relationship between dialysis and the blood. The procedure acts as a biological stimulus that triggers the body to churn out fresh clotting cells and activate the ones already present. The fact that the amount of heparin used influences this response is a new observation that warrants further investigation. While the study confirms that the blood undergoes a rapid, measurable transformation during dialysis, it stops short of saying this transformation is dangerous or beneficial on its own. The researchers conclude that these immature platelet markers are useful tools for watching how the body reacts to treatment, but more research is needed to understand if these changes matter for the long-term health and safety of the patients. For now, the picture is one of a body in constant, rapid adjustment, responding to the artificial kidney with a surge of new, active cells.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.